- BPharm: The Hebrew University of Jerusalem, Jerusalem, Israel (2001)
- MSc: The Hebrew University of Jerusalem, Jerusalem, Israel (2003)
- PhD: The Hebrew University of Jerusalem, Jerusalem, Israel (2008)
- Young Investigator Award: 6th International Workshop on Waldenstrom’s Macroglobulinemia (2010)
- AACR-Amgen, Inc. Fellowship in Clinical/Translational Cancer Research: American Association of Cancer Research (2010)
- Fellow Award: Multiple Myeloma Research Foundation (2008)
Kareem Azab, PhD, is an assistant professor of radiation oncology, Cancer Biology Division of the Department of Radiation Oncology since 2012. He earned a Ph.D. in Pharmaceutical Sciences from The Hebrew University of Jerusalem in 2007 and completed post-doctoral training focusing on cancer biology at Harvard Medical School/Dana Farber Cancer Institute in 2012. Professor Azab has co-authored more than 70 peer-reviewed papers and 10 patents. He is supported by the National Institute of Health, Multiple Myeloma Research Foundation, Waldenstrom’s Macroglobulinemia Foundation, Bear Cub entrepreneurship awards, and commercial awards from several pharmaceutical and biotech industry partners. Moreover, he is the founder of two startup companies Cellatrix LLC and Targeted Therapeutics LLC.
Dr. Azab conducts multi-disciplinary translational research with a focus on treatment and imaging of cancer, including hematologic malignancies and solid tumors. He works intensively on understanding the biological mechanisms of cancer progression and metastasis, development of novel drugs, targeted delivery of therapeutic agents (from nano-sized systems up to medical devices), and on developing patient-derived, tissue engineered pre-clinical models to study cancer.